Patent: 9,409,956
✉ Email this page to a colleague
Summary for Patent: 9,409,956
| Title: | Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof |
| Abstract: | Described herein is the generation of a plasmid construct for expression of a Yersinia pestis F1-V fusion protein. In the disclosed plasmid, the F1-V fusion protein coding sequence is operably linked to the E. coli htrA promoter, and is fused in-frame to the E. coli HlyA secretion signal sequence. Also described is Salmonella enterica serovar Typhi strain Ty21a containing the F1-V fusion protein expression plasmid, such as for use as an oral vaccine against plague. |
| Inventor(s): | Kopecko; Dennis J. (Silver Spring, MD), Osorio; Manuel (Bethesda, MD), Foote; Monica R. (North Potomac, MD) |
| Assignee: | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) |
| Application Number: | 14/402,457 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,409,956
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Emergent Travel Health, Inc. | VIVOTIF | typhoid vaccine live oral ty21a | Capsule | 103123 | 12/15/1989 | ⤷ Try a Trial | 2032-05-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
